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Abstract
Rationale: There is growing evidence that obstructive sleep apnea is associated with coronary
artery disease. However, there are no data on the course of coronary stenosis after percutaneous
coronary intervention in patients with obstructive sleep apnea.
Objectives: To determine whether sleep apnea is associated with increased late lumen loss and
restenosis after percutaneous coronary intervention.
Methods: 78 patients with coronary artery disease who underwent elective percutaneous
coronary intervention were divided in 2 groups: 43 patients with an apnea hypopnea – Index < 10/
h (group I) and 35 pt. with obstructive sleep apnea and an AHI > 10/h (group II). Late lumen loss,
a marker of restenosis, was determined using quantitative coronary angiography after 6.9 ± 3.1
months.
Main results: Angiographic restenosis (>50% luminal diameter), was present in 6 (14%) of group
I and in 9 (25%) of group II (p = 0.11). Late lumen loss was significant higher in pt. with an AHI >
10/h (0.7 ± 0.69 mm vs. 0.38 ± 0.37 mm, p = 0.01). Among these 35 patients, 21(60%) used their
CPAP devices regularly. There was a marginally lower late lumen loss in treated patients,
nevertheless, this difference did not reach statistical significance (0.57 ± 0.47 mm vs. 0.99 ± 0.86
mm, p = 0.08). There was no difference in late lumen loss between treated patients and the group
I (p = 0.206).
Conclusion: In summary, patients with OSA and coronary artery disease have a higher degree of
late lumen loss, which is a marker of restenosis and vessel remodeling after elective percutaneous
intervention.
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Obstructive sleep apnea (OSA) is a common disorder
defined by upper airway obstruction, apnea and nocturnal
hypoxia. There is a prevalence of OSA in patients with cor-
onary artery disease of up to 50% [1-3]. Beyond this high
prevalence, the occurrence of OSA is associated with an
advanced state of atherosclerosis [4] and a worse progno-
sis in these patients [5-7]. In the last decade, there is grow-
ing evidence that OSA acts as a cardiovascular risk factor,
independent of associated traditional risk factors (e.g.
arterial hypertension, dyslipedemia, obesitas).
Percutaneous transluminal coronary angioplasty (PTCA)
has proved effective in reducing myocardial ischemia and
clinical symptoms in patients with coronary artery disease
(CAD) with a primary success rate ranging from 90%–
95% in the general population. Although there are prom-
ising developments in interventional cardiology, late rest-
enosis is still an unsolved problem of interventional
procedures. Hemodynamic restenosis occurs after a
period of about 12 Weeks in 30–45% of the cases treated
with PTCA [8,9] and 20–30% of the cases with additional
coronary stent implantation using bare metal stents [10].
Yumino et al. found a high prevalence of OSA in patients
with acute coronary syndrome. In these patients OSA
appeared to be an independent predictor of clinical and
angiographic outcomes after percutaneous coronary inter-
vention (PCI) [11]. However, there are no data on the
course of coronary artery disease after elective PCI in sta-
ble patients with OSA. We hypothesized, that OSA is asso-




Candidates for participation were consecutive patients
undergoing elective coronary angiography and percutane-
ous coronary intervention and clinical suspected noctur-
nal breathing disorders (heavy snoring, obesity, daytime
sleepiness, history of witnessed apneas). All patients
underwent overnight-polygraphy (Schwarzer, Germany
[12]) between 10.00 p.m and 6.00 a.m. and were classi-
fied as sleep apneics or controls according to data of the
apnea hypopnea index (AHI). Oronasal airflow was regis-
tered using a thermistor, abdominal and thoracic respira-
tion efforts were measured using impendance
plethysmography. Oxygen saturation (SaO2) was meas-
ured using finger pulse oxymetry. The AHI was calculated
as the number of respiratory events per hour after manual
scoring. Minimal nocturnal oxygen saturation was
defined as the lowest saturation reached during sleep after
manual exclusion of clear artefacts. As adopted in previ-
ous studies [7,12] a threshold AHI of 10/h was accepted as
a diagnostic indicator for obstructive sleep apnea syn-
drome. Cardiovascular risk factors were defined as
described in a recent study [12]. The study complied with
the declaration of Helsinki. All procedures were carried
out as routine procedures, regardless of the study proto-
col. All patients gave their informed consent.
Treatment of OSA
All patients with an AHI > 10/h were offered CPAP ther-
apy. Patients with OSA were divided in two groups based
on whether they were treated with CPAP. When CPAP was
accepted, titration was performed during a second night
in the sleep laboratory using an Auto-CPAP device super-
vised by an experienced doctor (Somnosmart, Weinmann
Germany). The P95 read out from the titration device was
used to calculate constant CPAP [13]. The treatment
group comprised all patients who accepted CPAP therapy,
long term compliance was evaluated based on a personnel
questionaire. Patients were considered to be CPAP com-
pliant if they used CPAP on an average > 5 h per night,
determined at follow up. CPAP therapy was initiated after
the PCI and was performed until the date of the second
angiographic study.
Coronary angiography, percutaneuous coronary 
intervention, quantification of Restenosis
Selective coronary angiography was performed following
the administration of intracoronary glyceryl nitrate. At
least six standardized projections of the left coronary
artery and two of the right coronary artery were obtained.
Quantitative analysis of the angiograms was performed
(Quantcor, Siemens, [14]) at baseline and at follow up.
Before the intervention all patients received 500 mg acetyl
salicylic acid (ASA) i.v. and 5000–7500 iE Heparin (acti-
vated clotting time (ACT) > 300 sec.). Regular medication
includes ASA 100 mg p.o. in all patients and additionally
clopidogrel after stent implantation (300 mg loading dose
and 75/mg/d over 4 weeks). Coronary stents (bare metal
stents) were implantated in case of coronary dissection or
elastic recoil, as well as in calcified stenoses with deficient
results of balloon-angioplasty alone.
Follow up
Follow up coronary angiography was carried out in every
patient as a routine procedure after 6.9 ± 3.1 months,
regardless of the presence of clinical symptoms or results
from non-invasive measurements of myocardial ischemia.
Clinical relevant restenosis was defined as > 50% stenosis
of the initial target lesion at follow up. Late luminal loss
was determined using quantitative coronary arteriography
(minimum luminal diameter immediately after angi-
oplasty minus minimal luminal diameter at follow up).
Exclusion criteria
Exclusion criteria were: acute coronary syndrome, use of
drug eluting stents, failed angioplasty with a more thanPage 2 of 7
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PCI.
Statistics
The data were analyzed with the Statistical Package for
Social Sciences (SPSS 11.0 for Windows, Munich Ger-
many). For comparison of several groups the Mann-Whit-
ney U Test was used. Non-continuous data were analyzed
using the two tailed Fisher exact test. Correlation coeffi-
cients were generated with the Spearman test. A multivar-
iate logistic regression analysis was performed to assess
the predictive variables of late lumen loss. The included
variables were selected, if they were significant during uni-
variate analysis or were considered to be biologically rele-
vant. Significant difference between groups was assumed
at the level of error < 5%. Tests between 5% and 10% were
considered as statistical trends.
Results
Between 2001 and 2005 78 patients were included in the
study. Analysis of quantitative angiographic variables
showed, that the severity of the coronary stenosis (per
cent diameter stenosis before the intervention (r = -0.385,
p = 0.001) and immediately after the procedure (r =
0.674, p = 0.001)) was positively correlated with late
lumen loss, indicating, that severity of vessel injury is a
promotor of restenosis. There was no significant correla-
tion between late lumen loss and maximal balloon pres-
sure (r = -0.077, p = 0.522), or vessel diameter (r = 0.053,
p = 0.66).
Clinical characteristics were similar in patients with or
without sleep apnea, in both groups most of the patients
were men (see Table 1). There was a high prevalence of
cardiovascular risk factors. The proportion of patients
with a positive smoking history, arterial hypertension,
hyperlipoproteinemia, obesity or diabetes mellitus were
similar in both groups, as was the number of risk factors
per patient (3.19 ± 1.03 vs. 3.05 ± 1.05) (see Table 2).
There was no difference in left ventricular systolic func-
tion (Ejection fraction (66 ± 12% vs. 64 ± 16%)).
The predominant target vessel for intervention was the left
anterior descending artery (LAD) in both groups, and
there were no significant differences in complexity and
angulation of stenoses that were dilated.
Stent implantation was performed in 22 (51%) patients
with an AHI < 10/h, and in 23 (64%) patients of group II
(n.s.). There were no significant differences in respect of
periprocedural variables, such as balloon size or inflation
time between the two groups (see Table 3). Angiographic
restenosis, defined by the presence of a hemodynamically
relevant stenosis (>50% luminal diameter), was present in
6 (14%) of group I and in 9 (25%) of group II (p = 0.11).
Late lumen loss was significantly higher in OSA-patients
(0.7 ± 0.69 mm vs. 0.38 ± 0.38 mm, p = 0.01).
Stepwise multiple linear regression analyses were con-
ducted to determine relations of gender, age, BMI, cardio-
vascular risk factors (diabetes mellitus, arterial
hypertension, hyperlipoproteinemia) and lesion mor-
phology with late lumen loss. An apnea hypopnea index
> 10/h, and minimal luminal diameter of the coronary
segment were significant predictors of late lumen loss. An
AHI > 10/h remained a significant predictor of late lumen
loss after adjusting for cardiovascular risk factors as diabe-
tes mellitus, hypertension, hyperlipidemia and body mass
index.
Among the 35 patients with an AHI > 10/h, 21 (60%)
accepted treatment with CPAP and used their devices reg-
ularly. Although CPAP users had a higher BMI, there was
no difference in apnea hypopnea index or minimal noc-
turnal oxygen saturation at baseline. There was a margin-
Table 1: Clinical characteristics and cardiovascular treatment at 
baseline. Plus/minus values are means ± SD.
Control n = 43 OSA n = 35 p
Age (y) 65.1 ± 9.6 67.4 ± 7.3 0.17
Male n (%) 39 (90.7) 32 (91.4) 0.66
BMI (kg/m2) 27.9 ± 4.6 28.1 ± 4.0 0.82
AHI (events/h) 3.8 ± 2.5 27.5 ± 16.6 < 0.001
Min SaO2 (%) 89.3 ± 3.2 83.8 ± 4.0 < 0.001
Medication
Platelet inhibitor, n (%) 40 (93) 33 (94.3) 0.82
Beta Blocker, n (%) 33 (76) 25 (71.4) 0.59
ACE Inhibitor, n (%) 30 (69.8) 25 (71.4) 0.87
Statin, n (%) 34 (79.1) 26 (74.3) 0.62
Late lumen loss in patients without obstructive sleep apnea, OSA patients withou  treatment and OSA patients with effective CPAP ther pyFigure 1
Late lumen loss in patients without obstructive sleep apnea, 
OSA patients without treatment and OSA patients with 
effective CPAP therapy.
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treated OSA patients, nevertheless, this difference did not
reach statistical significance (0.57 ± 0.47 mm vs. 0.99 ±
0.86 mm, p = 0.08) (see Table 4). There was no significant
difference in late lumen loss after percutaneous coronary
intervention between group I and treated patients of
group II (Fig. 1).
Discussion
Although there is growing evidence that obstructive sleep
apnea is associated with coronary artery disease and cardi-
ovascular events, this is the first study which focuses on
the problem of restenosis after elective coronary interven-
tion in these patients. Based on quantitative coronary ang-
iography, late lumen loss, which is a marker of restenosis
and vascular remodeling, was enhanced in OSA-patients.
The rate of hemodynamically relevant angiographic reste-
nosis >50% was almost 2-fold higher in patients with OSA
(25%) compared to patients without sleep apnea (14%),
although there was no statistically significance. Sleep
apneics who regularly performed CPAP showed a slight
decrease of late lumen loss, implicating, that this therapy
might have beneficial effects with regard to restenosis and
the clinical course of coronary artery disease in OSA
patients.
There are several pathomechanisms contributing to cardi-
ovascular risk in OSA: increase of sympathetic nervous
system activity [15], decrease in heart rate variability,
endothelial damage and dysfunction [16,17], platelet acti-
vation, increase in blood coagulability [12] and insulin
resistance [18]. In a 7 year follow up study, patients with
OSA had a 4.9 fold greater risk of developing cardiovascu-
lar disease during the follow up, independent of other risk
factors [1] Our data support the hypothesis, that coronary
occlusion might be one reason for the worse prognosis
and outcome in these patients. Further on, the data impli-
cate, that OSA-patients carry an increased risk of resteno-
sis potentially associated with clinical events following
percutaneous coronary interventions. This is in concert
with a recent study which found OSA to be associated
with increased cardiac death after percutaneous coronary
intervention [19].
Table 2: Cardiovascular risk profile in control and obstructive sleep apnea
Control n = 43 OSA n = 35 p
HTN n (%) 35 (81.3) 27 (77) 0.64
RRsys (mmHg) 133 ± 17 135 ± 15 0.51
RRdia (mmHg) 78 ± 11 77 ± 10 0.64
HLP, n (%) 40 (93) 34 (97) 0.82
Smoker/Ex-Smoker, n (%) 3 (6.9)/22 (51.1) 5 (14.2)/21 (60)
Packyears (n) 15 ± 19 22 ± 22 0.16
Diabetes mellitus, n (%) 8 (18.6) 8 (22.8) 0.64
Family History (CAD), n (%) 17 (39.5) 15 (42.8) 0.96
Number of Risk factors per patient 3.19 ± 1.03 3.05 ± 1.05 0.73
Laboratory variables
Total Cholesterol (mg/dl) 193 ± 41 190 ± 43 0.63
LDL Cholesterol (mg/dl) 126 ± 38 120 ± 31 0.40
HDL Cholesterol (mg/dl) 52 ± 20 49 ± 12 0.51
LDL/HDL 2.8 ± 1.3 3.1 ± 4.0 0.66
Table 3: Angiographic findings and periprocedural variables in patients with and without obstructive sleep apnea.
Control n = 43 OSA n = 35 p
Follow up period (months) 7.1 ± 2.7 6.7 ± 3.7 0.43
Ejection fraction (%) 66 ± 12 64 ± 16 0.84
Coronary artery narrowed (RCA/LAD/LCX) 14/20/9 8/17/10
Type of lesion A/B/C 20/17/6 17/11/7
Reference diameter (mm) 2.89 ± 0.43 3.04 ± 0.56 0.18
Final balloon size (mm) 2.98 ± 0.42 3.01 ± 0.47 0.76
Maximal inflation pressure (atm) 11.2 ± 2.8 10.4 ± 2.5 0.20
Total inflation time (sec) 89 ± 53 78 ± 45 0.38
Stent, n (%) 22 (51) 23 (64) 0.11
Restenosis > 50%, n (%) 6 (14) 9 (26) 0.11
Late lumen loss (mm) 0.38 ± 0.38 0.7 ± 0.69 0.01Page 4 of 7
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oplasty showed renarrowing at the side of angioplasty to
be a gradual, time-related phenomenon which appeared
to reach a zenith at 4–6 month [8,20]. There are different
aspects of the late result of coronary intervention: the out-
come of the patients, and, from the anatomical point of
view, the angiographic result determined by the diameter
of the vessel/lesion site at its narrowest point ("minimal
luminal diameter"). The renarrowing occurring from
immediately after the intervention over the following 6
months as determined and quantified by the follow angi-
ogramm conveys the degree of new tissue growth and ves-
sel remodeling [8], factors, which might be influenced by
intermittend nocturnal hypoxemia in patients with OSA.
In this regard, there is only one study investigating the
contribution of nocturnal hypoxemia to the development
of restenosis after percutaneous coronary intervention.
Hayashi et al. [21] used nocturnal oxymetry as a screening
tool for OSA after stent placement in a small group of 35
patients with coronary artery disease. They suggested, that
nocturnal hypoxemia may be associated with coronary
restenosis. Nevertheless, confirmation of the diagnosis of
sleep apnea syndrome could not be established. Milleron
et al. [5] report on a group of 54 patients with sleep apnea
and coronary artery disease. They found, in concert with
our findings, that OSA was associated with a higher rate of
cardiovascular events e.g. revascularization or myocardial
infarction in untreated OSA patients.
There is evidence, that restenosis is affected by inflamma-
tory processes [22]. It is supposed, that nocturnal hypox-
emia causes inflammation. In this regard it was shown,
that OSA is associated with an elevated C-reactive proteine
[23,24], Interleukin-6 [24], serum amyloid A [25] and ele-
vated Fibrinogen and plasma viscosity [12]. In addition,
most of these parameters were normalized using CPAP-
Therapy in patients with OSA, indicating a causative role
of OSA in the inflammatory process. Since inflammation
might play a central role in renarrowing of the vessels in
OSA patients, the role of drug eluting stents has to be
assessed in these patients.
CPAP therapy is recommended in any OSA patient with
an AHI exceeding 30/h or at a minimal threshold of 5/h if
the patient is suffering symptoms like daytime sleepiness,
impaired cognition, insomnia or cardiovascular disease
[26]. Futhermore, recent studies support a protective
effect of CPAP therapy with regard to death from cardio-
vascular disease in patients with OSA [27] and indicate,
that CPAP is associated with a decrease in the occurrence
of new cardiovascular events, and an increase in the time
to such events [5]. According to the results of the Sleep
Heart Health Study [28] it seems prudent to advocate
CPAP therapy in patients with CAD and moderate OSA,
even if they do not suffer from excessive daytime sleepi-
ness [8]. In our study, only 60% of the OSA patients
accepted CPAP and used their device regularly. However,
this rate might be optimized if CPAP is not only recom-
mended as a means of controlling symptoms of OSA but
also as part of their CAD treatment. In this regard it was
shown, that adherence to CPAP might reach nearly 100%
in patients with coronary artery disease and sleep apnea,
even without daytime sleepiness [29]. By all means,
patients with risk profile for OSA (e.g. obesity, sleepiness)
should be screened for nocturnal breathing disorders to
optimize cardiovascular risk and the risk of restenosis
after percutaneous coronary intervention.
Limitations of the study
There are several limitations of the study: first of all, we
did not carry out overnight polysomnography, therefore
we can not rule out sleep relating breathing disorders in
Table 4: Angiographic findings and periprocedural variables in patients with obstructive sleep apnea with regard to CPAP treatment.
No CPAP n = 14 CPAP n = 21 p
Severity of OSA
BMI (kg/m2) 26.4 ± 3.3 29.3 ± 4.2 0.04
AHI (ev/h) 26.3 ± 17.6 27.4 ± 16.0 0.8
Min SaO2 (%) 83.6 ± 4.3 82.8 ± 3.9 0.9
Arteriogramm and lesion characteristics
Coronary artery narrowed (RCA/LAD/LCX) 2/9/3 6/8/7
Type of lesion A/B/C 9/2/3 8/9/4
Reference diameter (mm) 3.0 ± 0.6 3.1 ± 0.6 0.82
Final balloon size (mm) 3.1 ± 0.5 2.9 ± 0.4 0.25
Maximal inflation pressure (atm) 9.4 ± 1.8 11 ± 2.8 0.07
Total inflation time (sec) 70 ± 36 84 ± 50 0.41
Stent, n (%) 7 (50) 15 (71) 0.09
Restenosis > 50%, n (%) 4 (28.6) 5 (23.8) 0.32
Late loss (mm) 0.99 ± 0.86 0.57 ± 0.47 0.08
Ejection fraction (%) 61 ± 15 67 ± 16 0.28Page 5 of 7
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and AHI are the common parameters describing the sever-
ity of nocturnal breathing disorders. Furthermore, there
were no follow up sleep studies at the time of the second
angiography study. Another limitation refers to the study
design, since there was no randomization of the OSA
patients with regard to CPAP. Therefore, we can not
exclude some misclassification bias. In this regard, there
was a higher rate of stent placements in patients with
CPAP-therapy compared to patients without CPAP-ther-
apy within the OSA group, which might have contributed
to the less pronounced late lumen loss in CPAP treated
patients. Further limitation refers to the study design,
which does not allow to verify a causal relationship.
In summary, patients with OSA and coronary artery dis-
ease have a higher degree of late lumen loss, which is a
marker of restenosis and vessel remodeling after elective
percutaneous intervention.
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